No Detail Found!

Effacy and safety profile of lenalidomide vs lenalidomide + R-CHOP in patients with diffuse large B cell lymphoma: A systematic review

Author(s)
Muhammad Sajjad Ali Ayub Medical College, Abbottabad, Pakistan
Shahzaib Maqbool Rawalpindi Medical University, Rawalpindi, Pakistan
Azeen Razzaq Rawalpindi Medical University, Rawalpindi, Pakistan
Abdur Rehman Rawalpindi Medical University, Rawalpindi, Pakistan
Salman Yousaf Services Institute of Medical Sciences, Lahore, Pakistan
Muhammad Farhan Allama Iqbal Medical College, Lahore, Pakistan
Maryam Farhan Baloch Allama Iqbal Medical College, Lahore, Pakistan
Muhammad Abdul Khaliq Khan Baqai Medical university, Karachi, Pakistan
Abstract
The most frequent cause of non-Hodgkin lymphoma, which accounts for around one-third of cases, is diffuse large B cell lymphoma (DLBCL). Immune chemotherapy combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard therapy for DLBCL. Objective: To analysing the utilization of Lenalidomide versus Lenalidomide R-CHOP regimen in treatment of DLBCL in terms of treatment e??cacy and safety. Methods: PRISMA guidelines were followed for conducting this study. A thorough literature search was done from November 15 to November 25, 2022. A variety of databases, including PubMed, Google Scholar, and other, were used to conduct the literature search. Finally, for this systematic review, 10 studies were chosen. Results: In our study the monotherapy with Lenalidomide was found less signi??cant in terms of improvement in Overall response rate, complete response among patients with DLBCL. However; Lenalidomide + R-CHOP was more effective in improving overall response rate (ORR) with ORR of 92.89% vs 30.58% and complete response rate (CRR) of 80.20% vs 12.53%. The partial response rate (PR) was comparable between two therapies. similarly, the Progression free survival was also better in combination therapy. Haematological and Non-Hematological adverse effects of grade >3 were found higher among patients with combination therapy and Neutropenia was commonly observed adverse effect. Conclusions: Combination therapy was associated with signi??cant improvement in disease outcome, however; the adverse effects were reported high in combination therapy vs monotherapy..
Publication Details
Page(s) 71-77
Published Journal: Pakistan Journal of Health Sciences, Volume: 4, Issue: 8, Year: 2023

Request the full text from PASTIC

Keywords
Lenalidomide, DLBCL, Lenalidomide + R-CHOP
0

Citations

0

Downloads

58

Views